Articles By Wayne Koberstein

1. Write Thinking — Biopharma At the Turn of the Year 12/31/2015

   Writing is reinforced thinking. It is a stronger, more constructive way of moving through the thought world. Because I am a trade journalist covering the life science industry, all of those things tend to appear to me in industry terms. Take the drug-pricing debate, for example. 

    

2. Love Me, Love Me Not — The Life Science Industry’s Paradox 5/28/2015

   Cold-hearted logic dominates the quest for shareholder value, even as industry insiders complain that “nobody loves us.” What better example of the conundrum exists than the current commentary about Gilead and its wonder drugs for Hep C?

3. Life Science Partnerships With Patient Foundations: Best Practices - Part 3 7/31/2014

   Voices of BayBio’s "Successful Public-Private Partnerships" Survey

4. Arsanis Biosciences Is Fighting The Nastiest Bacteria With Monoclonal Antibodies 7/31/2014

   A pioneer and crusader in the almost-abandoned field of antibiotics is out to show the world how to fight the nastiest bacteria with monoclonal antibodies.

5. Boehringer Ingelheim Ups The Ante In Treating Lung Disorders 7/31/2014

   Tunde Otulana, M.D., heads Boehringer Ingelheim’s clinical development and medical affairs group. He is a former FDA reviewer who studied, learned, and finally got the chance to apply his knowledge of clinical trials when he stepped over into industry in 1997. As a pulmonologist who previously worked for about seven years in the FDA’s pulmonary division, Otulana subsequently led related R&D efforts at several companies before coming to BI in 2011. He now plays a key role in the U.S. in preserving the company’s position as a pioneer and leader in respiratory therapy, mainly in chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

6. Millennium Carries On With The Takeda Oncology Expansion 6/30/2014

   Since I’ve been writing about the pharma industry for many years, I often find it impossible to walk in any direction without bumping into a connection from the past. It seems like a thousand years ago that I interviewed Millennium’s founder, Mark Levin, soon after the launch of its hallmark cancer drug. Certainly enough has transpired since then.

7. Eli Lilly Navigates The Realities Of Innovation 6/2/2014

   You have seen the headlines, reading like obituaries for the about-to-be departed. You know the drill: repeated failures in Phase 3, nothing to replace the big earners with vanishing patents, mental images of a ship lost at sea. So why is Eli Lilly & Company still here — sailing the same course, undiverted, undiluted, and seemingly undeterred as the uniquely independent Midwestern-based company it has always been?

8. Paul Stoffels Expands The Janssen Legacy 3/3/2014

   Speaking with Paul Stoffels is like continuing a long-ago conversation with the late Paul Janssen. A generation younger than the original Janssen company founder, Stoffels now has responsibilities similar to his former boss and mentor, but for a much bigger and more complex company now under the Janssen name.

9. Janet Woodcock’s Quality Agenda At CDER 2/2/2014

   New mandates, new user fees, and new uncertainties occupy the FDA’s drug center in 2014.

10. Companies To Watch: Proteon Therapeutics 12/2/2013

    Proteon Therapeutics has the singular purpose of treating the bane of nearly all kidney dialysis patients – stenosis and failure of the surgically placed vascular access for hemodialysis.